Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV
Authors:
- Chishala ChabalaCCChishala Chabala
- Anna TurkovaATAnna Turkova
- Monica KapasaMKMonica Kapasa
- Kristen LeBeauKLKristen LeBeau
- Chimuka H. TemboCTChimuka H. Tembo
- Kevin ZimbaKZKevin Zimba
- Khozya ZyamboKZKhozya Zyambo
- Louise ChooLCLouise Choo
- Chalilwe ChunguCCChalilwe Chungu
- Joyce LunguJLJoyce Lungu
- Veronica MulengaVMVeronica Mulenga
Open Access
- 20 July 2023
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 42 (10) , 899-904
Abstract
Background: Lopinavir/ritonavir plasma concentrations are profoundly reduced when co-administered with rifampicin. Super-boosting of lopinavir/ritonavir is limited by nonavailability of single-entity ritonavir, while double-dosing of co-formulated lopinavir/ritonavir given twice-daily produces suboptimal lopinavir concentrations in young children. We evaluated whether increased daily dosing with modified 8-hourly lopinavir/ritonavir 4:1 would maintain therapeutic plasma concentrations of lopinavir in children living with HIV receiving rifampicin-based antituberculosis treatment. Methods: Children with HIV/tuberculosis coinfection weighing 3.0 to 19.9 kg, on rifampicin-based antituberculosis treatment were commenced or switched to 8-hourly liquid lopinavir/ritonavir 4:1 with increased daily dosing using weight-band dosing approach. A standard twice-daily dosing of lopinavir/ritonavir was resumed 2 weeks after completing antituberculosis treatment. Plasma sampling was conducted during and 4 weeks after completing antituberculosis treatment. Results: Of 20 children enrolled; 15, 1–7 years old, had pharmacokinetics sampling available for analysis. Lopinavir concentrations (median [range]) on 8-hourly lopinavir/ritonavir co-administered with rifampicin (n = 15; area under the curve0–24 55.32 mg/h/L [0.30–398.7 mg/h/L]; Cmax 3.04 mg/L [0.03–18.6 mg/L]; C8hr 0.90 mg/L [0.01–13.7 mg/L]) were lower than on standard dosing without rifampicin (n = 12; area under the curve24 121.63 mg/h/L [2.56–487.3 mg/h/L]; Cmax 9.45 mg/L [0.39–26.4 mg/L]; C12hr 3.03 mg/L [0.01–17.7 mg/L]). During and after rifampicin cotreatment, only 7 of 15 (44.7%) and 8 of 12 (66.7%) children, respectively, achieved targeted pre-dose lopinavir concentrations ≥1mg/L. Conclusions: Modified 8-hourly dosing of lopinavir/ritonavir failed to achieve adequate lopinavir concentrations with concurrent antituberculosis treatment. The subtherapeutic lopinavir exposures on standard dosing after antituberculosis treatment are of concern and requires further evaluation.Keywords
This publication has 18 references indexed in Scilit:
- Acceptability of Lopinavir/R Pellets (Minitabs), Tablets and Syrups in HIV-Infected ChildrenAntiviral Therapy, 2015
- The Effect of Malnutrition on the Pharmacokinetics and Virologic Outcomes of Lopinavir, Efavirenz and Nevirapine in Food Insecure HIV-infected Children in Tororo, UgandaThe Pediatric Infectious Disease Journal, 2015
- The Pharmacokinetics and Acceptability of Lopinavir/Ritonavir Minitab Sprinkles, Tablets, and Syrups in African HIV-Infected ChildrenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2014
- Tuberculosis and HIV co-infection in childrenBMC Infectious Diseases, 2014
- The Safety, Effectiveness and Concentrations of Adjusted Lopinavir/Ritonavir in HIV-Infected Adults on Rifampicin-Based Antitubercular TherapyPLOS ONE, 2012
- Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-Based Antitubercular Treatment in HIV-Infected ChildrenAntiviral Therapy, 2012
- Lopinavir Exposure is Insufficient in Children Given Double Doses of Lopinavir/Ritonavir during Rifampicin-Based Treatment for TuberculosisAntiviral Therapy, 2010
- Effect of Rifampicin on Lopinavir Pharmacokinetics in HIV-Infected Children With TuberculosisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Plasma Concentrations of the HIV-Protease Inhibitor Lopinavir are Suboptimal in Children Aged 2 Years and BelowAntiviral Therapy, 2007
- Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2004